Furen R. Zhang

27397 Jingshi Road
Jinan, 250022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 286 publications

Trends in severe cutaneous adverse drug reactions before, during, and after the COVID-19 pandemic: A retrospective multicenter study of 794 cases.

Trends in severe cutaneous adverse drug reactions before, during, and after the COVID-19 pandemic: A retrospective multicenter study of 794 cases.

Journal: JAAD international

Published: August 09, 2026

Combination of concentrated growth factor and collagen filler for recalcitrant atrophic scars: Two case reports.

Combination of concentrated growth factor and collagen filler for recalcitrant atrophic scars: Two case reports.

Journal: JAAD case reports

Published: July 19, 2026

Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.

Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.

Journal: The Journal of dermatological treatment

Published: July 15, 2026

The master regulators of delayed-type drug hypersensitivity reactions.

The master regulators of delayed-type drug hypersensitivity reactions.

Journal: Current opinion in allergy and clinical immunology

Published: June 03, 2026

Analysis of influencing factors for syphilis serofast and development and evaluation of a predictive model.

Analysis of influencing factors for syphilis serofast and development and evaluation of a predictive model.

Journal: Frontiers in immunology

Published: June 02, 2026

IgG subclasses and their significance in pemphigus disease progression monitoring.

IgG subclasses and their significance in pemphigus disease progression monitoring.

Journal: Frontiers in immunology

Published: May 30, 2026

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Journal: The British journal of dermatology

Published: May 21, 2026

Clinical Predictors and a Novel Diagnostic Nomogram for Non-Bullous Pemphigoid: A 10-year Large-Scale Retrospective Case-Control Study.

Clinical Predictors and a Novel Diagnostic Nomogram for Non-Bullous Pemphigoid: A 10-year Large-Scale Retrospective Case-Control Study.

Journal: Journal of the American Academy of Dermatology

Published: May 12, 2026

Proteomic Profiling Reveals a Cytokine-Chemokine Axis Involving CXCL10, CD40, and CCL17 in Dermatitis Herpetiformis Pathogenesis and Treatment Response.

Proteomic Profiling Reveals a Cytokine-Chemokine Axis Involving CXCL10, CD40, and CCL17 in Dermatitis Herpetiformis Pathogenesis and Treatment Response.

Journal: The British journal of dermatology

Published: May 07, 2026

Omeprazole activation of CD4+ and CD8+ T-cells through off-target covalent modification of cellular proteins.

Omeprazole activation of CD4+ and CD8+ T-cells through off-target covalent modification of cellular proteins.

Journal: Toxicological sciences : an official journal of the Society of Toxicology

Published: April 27, 2026

Comparison of fluorescence and light microscopy for the quantification of Demodex mites: A prospective cross-sectional study.

Comparison of fluorescence and light microscopy for the quantification of Demodex mites: A prospective cross-sectional study.

Journal: Journal of the American Academy of Dermatology

Published: April 19, 2026

TNF-alpha is a master regulator of drug-specific T-cell activation.

TNF-alpha is a master regulator of drug-specific T-cell activation.

Journal: The Journal of allergy and clinical immunology

Published: March 27, 2026

Showing 1-12 of 286

Last Updated: 09/26/2026